iBody Directed towards Glutamate Carboxypeptidase II
Anti-GCPII iBody is able to specifically target and bind glutamate carboxypeptidase II, a transmembrane metallopeptidase that is strongly expressed in prostate carcinoma. The ligand used for specific targeting is GCPII inhibitor which binds the enzyme with extremely high affinities. Anti-GCPII iBody is also accessorized with ATTO 488 fluorophore, which serves as a tool for facile detection and visualization of the protein. Furthermore, biotin, which assists in immobilization of the protein of interest and potentially in additional detection with chemiluminesce, is conjugated to the polymer carrier.
anti-GCPII iBodies® serve as a replacement for monoclonal anti-GCPII antibodies in a variety of biochemical applications such as immunoprecipitation, protein immobilization, ELISA, confocal microscopy, cytometry etc. iBodies bind GCPII with extremely high affinity with KDs in picomolar range.
Fig.1: iBody live cell imaging: Visualization of cells expressing GCPII (GCPII+) and with anti-GCPII iBody. Negative controls (NC): NC GCPII- = cells not expressing GCPII, NC iBody = iBody lacking GCPII inhibitor
Targeted biomolecule specification:
Glutamate carboxypeptidase (GCP) II, also known as Prostate-Specific Membrane Antigen (PSMA) is a membrane metallopeptidase expressed in the brain. GCPII is overexpressed in prostate cancer and tumor vasculature.
Targeting ligand: tight‐binding GCPII inhibitor
Fig. 2: Chemical structure of the GCPII inhibior
Affinity anchor: biotin
iBody KD (GCPII) = 4 pM; verified by SPR (KD < 20 pM)
The iBody is stable at room temperature. For long term storage, place the solution to -20°C.
Angew Chem Int Edit 2016, 55, 2356-2360